Aptamer-immobilized bone-targeting nanoparticles in situ reduce sclerostin for osteoporosis treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. A broader strategy for osteoporosis interventions10.1038/s41574-020-0339-7 ↗
2. The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey10.1002/jbmr.3757 ↗
3. Mechanisms of bone development and repair10.1038/s41580-020-00279-w ↗
4. Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP)
5. Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis10.1186/s12951-019-0447-5 ↗
6. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis10.1038/s41598-020-68037-8 ↗
7. Dental implants in osteoporotic patients taking oral bisphophonates: a literature review
8. Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate
9. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis10.1177/1759720X19877994 ↗
10. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains10.1038/s41467-020-19155-4 ↗
11. Bone sclerostin and dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis10.1186/s12891-021-04365-8 ↗
12. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: a review10.15586/jptcp.v27i1.655 ↗
13. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis10.1038/s41574-020-00426-5 ↗
14. Q. Lyu, Therapeutic potential of nucleic acid aptamers against sclerostin in the treatment of osteoporosis, in Conference Proceedings. 2017, Hong Kong Baptist University.
15. Mesoporous silica nanoparticles for the treatment of complex bone diseases: bone cancer, bone infection and osteoporosis10.3390/pharmaceutics12010083 ↗
16. Nanoparticles mimicking viral surface topography for enhanced cellular delivery10.1002/adma.201302737 ↗
17. Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres10.1021/nl404316v ↗
18. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems10.1021/bc034090j ↗
19. Aptamer functionalized nanomaterials for biomedical applications: Recent advances and new horizons10.1016/j.nantod.2021.101177 ↗
20. Nanotoxicology and nanomedicine: The Yin and Yang of nano-bio interactions for the new decade10.1016/j.nantod.2021.101184 ↗
21. Dendritic mesoporous organosilica nanoparticles (DMONs): Chemical composition, structural architecture, and promising applications10.1016/j.nantod.2021.101231 ↗
22. Bisphosphonate conjugation for bone specific drug targeting10.1016/j.bonr.2018.06.007 ↗
23. Alendronate-decorated nanoparticles as bone-targeted alendronate carriers for potential osteoporosis treatment10.1021/acsabm.1c00199 ↗
24. DNA adsorbed on hydroxyapatite surfaces10.1039/C4TB01184H ↗
25. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: a general review
26. Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis10.1111/jcmm.15084 ↗
27. Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model10.22203/eCM.v037a20 ↗
28. Hemocompatibility investigation and improvement of near-infrared persistent luminescent nanoparticle ZnGa2O4:Cr3+ by surface PEGylation10.1039/C9TB00378A ↗
29. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
30. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-1910.1038/s41565-021-00923-2 ↗
31. Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles10.1038/s41467-019-13316-w ↗
32. Progress, challenges, and future of nanomedicine10.1016/j.nantod.2020.101008 ↗
33. Bone-targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy10.1016/j.omtm.2020.04.010 ↗
34. Inhibition of osteoclast differentiation and bone resorption by bisphosphonate-conjugated gold nanoparticles10.1038/srep27336 ↗
35. Osteoporosis remission and new bone formation with mesoporous silica nanoparticles10.1002/advs.202101107 ↗
36. Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis10.1080/10717544.2017.1347966 ↗
37. A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively10.1039/D0RA00685H ↗
38. A review on natural teeth whitening10.1016/j.job.2021.12.002 ↗
39. Dispersion of nanoparticles in different media importantly determines the composition of their protein corona10.1371/journal.pone.0169552 ↗
40. Dispersion of nanomaterials in aqueous media: towards protocol optimization
41. Nanoparticles for the treatment of osteoporosis10.3934/bioeng.2017.2.259 ↗
42. Single-micelle-directed synthesis of mesoporous materials10.1038/s41578-019-0144-x ↗
43. Theranostic nanoparticles with disease-specific administration strategies10.1016/j.nantod.2021.101335 ↗
44. Programmable drug release using bioresponsive mesoporous silica nanoparticles for site-specific oral drug delivery10.1039/C4CC00620H ↗
45. Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport10.1021/acsnano.8b04315 ↗